Project Description
Professor Jeffrey Lipman
Ambassador for Research
Professor Lipman is a Senior Consultant Specialist in the Intensive Care at the Royal Brisbane and Women’s Hospital, and also Head of the Discipline of Anaesthesiology and Critical Care for The University of Queensland’s medical program. He is site Principal Investigator for numerous multi-national and international trials. Research interests include all aspects of management in intensive care, resuscitation of burns and particularly pharmacokinetics of antibiotic dosage. His research into antibiotic usage in acute situations has received international recognition whilst he has received multiple national and international awards. Professor Lipman is involved in most research projects, oversees the direction of the research centre, mentors staff and supervises postgraduate students.
Antibiotic pharmacokinetics and dosing in the critically ill
- Sepsis
- Pharmacokinetic/dynamic assessments
BLING III: A phase III randomised controlled trial of continuous beta-lactam infusion compared with intermittent beta-lactam dosing in critically ill patients. Principal Site Investigator: J Lipman
Ceftolozane/Tazobactam EVD: A prospective observational pharmacokinetic evaluation of the plasma and cerebrospinal fluid concentrations of a single dose ceftolozane/tazobactam in infected critically ill patients with an indwelling external ventricular drain. Principal Site Investigators: J Roberts, J Lipman
Microsampling: Validation of microsampling versus traditional blood sampling for antibiotic pharmacokinetics. Principal Site Investigators: J Lipman, S Wallis
PLUS: A multi-centre, blinded, randomised, controlled trial to determine whether fluid resuscitation and therapy with a “balanced” crystalloid solution (Plasma-Lyte 148®) decreases 90-day mortality in critically ill patients requiring fluid resuscitation when compared to the same treatment with 0.9% sodium chloride (saline). Principal Site Investigator: J Lipman
Evolution of Beta lactam resistance in pseudomonas aeruginosa during treatment of major burn injury. J Lipman
A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Clinical Trial to Study the Safety, Tolerability, and Efficacy of Imipenem/Cilastatin/Relebactam (MK-7655A) Versus Piperacillin/Tazobactam in Subjects with Hospital-Acquired Bacterial Pneumonia or Ventilator-Associated Bacterial Pneumonia J Lipman
Email: j.lipman@uq.edu.au
Phone: (07) 3646 8897